Stock Events

Stock Events

Supernus 

$29.20
21
-$0.25-0.85%Thursday 21:00
-$0.01-0.03%00:30After hours

Statistics

Day High
29.27
Day Low
29.19
52W High
42.81
52W Low
25.92
Volume
120,325
Avg. Volume
-
Mkt Cap
1.7B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Nov 2026
$8.13
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

Feb 18Expected
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Q3 2026
Next
0.3
0.64
0.98
1.32
Expected EPS
0.869667
Actual EPS
N/A

Financials

-5.36%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
718.95MRevenue
-38.55MNet Income

Analyst Ratings

$60.33Average Price Target
The highest estimate is ⁦87.00⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SUPN. It's not an investment recommendation.
Pfizer
7
PFE
Apple
6
AAPL
Microsoft
6
MSFT
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap49.72B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing directly with Supernus in the CNS and neurology markets.
Jazz Pharmaceuticals
JAZZ
Mkt Cap15.07B
Jazz Pharmaceuticals focuses on developing and commercializing innovative pharmaceuticals, including for neurological conditions, directly competing with Supernus.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.67B
ACADIA Pharmaceuticals specializes in the development and commercialization of medicines to treat central nervous system disorders, competing in similar markets as Supernus.
Alkermes
ALKS
Mkt Cap7.71B
Alkermes plc is involved in the development and commercialization of pharmaceuticals for CNS diseases, including schizophrenia and depression, areas where Supernus also operates.
Neurocrine Biosciences
NBIX
Mkt Cap16.66B
Neurocrine Biosciences develops and markets pharmaceuticals for neurological and endocrine-related diseases and disorders, competing in the same therapeutic areas as Supernus.
AMGEN
AMGN
Mkt Cap249.05B
Amgen, a biotechnology giant, has a diverse portfolio that includes treatments for neurological disorders, indirectly competing with Supernus in some areas.
Biogen
BIIB
Mkt Cap36.71B
Biogen focuses on neurology, and its portfolio includes treatments for multiple sclerosis and spinal muscular atrophy, competing with Supernus in the neurology space.
Abbvie
ABBV
Mkt Cap514.92B
AbbVie has a broad portfolio that includes CNS treatments, such as Parkinson's and Alzheimer's disease medications, making it a competitor in the neurology market.

About

Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.
Show More
CEO
Jack A. Khattar
Employees
827
Country
United States
ISIN
US45579U1097
WKN
000A1JX3U

Listings

STU
DE
S49.STU
LSE
GB
0LB2.LSE
BOATS
BOATS
SUPN.BOATS
XNAS
US
SUPN

0 Comments

Share your thoughts

FAQs

What is Supernus stock price today?▼
The current price of SUPN is $29.20 USD — it has decreased by -0.85% in the past 24 hours. Watch Supernus stock price performance more closely on the chart.
What is Supernus stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Supernus stocks are traded under the ticker SUPN.
Is Supernus stock price growing?▼
SUPN stock has risen by +11.62% compared to the previous week, the month change is a -30.49% fall, over the last year Supernus has showed a -34.29% decrease.
What is Supernus market cap?▼
Today Supernus has the market capitalization of 1.7B
When is the next Supernus earnings date?▼
Supernus is going to release the next earnings report on February 18, 2027.
What were Supernus earnings last quarter?▼
SUPN earnings for the last quarter are 1.32 USD per share, whereas the estimation was 1.06 USD resulting in a +24.45% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Supernus revenue for the last year?▼
Supernus revenue for the last year amounts to 718.95M USD.
What is Supernus net income for the last year?▼
SUPN net income for the last year is -38.55M USD.
Does Supernus pay dividends?▼
Yes, SUPN dividends are paid en. The last dividend per share was 8.13 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does Supernus have?▼
As of November 13, 2026, the company has 827 employees.
In which sector is Supernus located?▼
Supernus operates in the Health & Wellness sector.
When did Supernus complete a stock split?▼
Supernus has not had any recent stock splits.
Where is Supernus headquartered?▼
Supernus is headquartered in Rockville, United States.